









Markets
/
Stocks
/
nasdaq-lptx
/

Leap Therapeutics Inc

LPTX

View Detailed Chart

0.334USD

+0.028+9.15%

Market hours （ET）Quotes delayed by 15 min

13.84MMarket Cap

LossP/E TTM



Leap Therapeutics Inc

0.334

+0.028+9.15%

Overview Company Financials

Financials

Intraday

30m

Today

+9.15%

5 Days

-7.14%

1 Month

+14.62%

6 Months

-36.19%

Year to Date

-88.38%

1 Year

-83.75%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 1 analysts

HOLD

Current Rating

3.000

Target Price

669.23%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

552

Total

Median

Average

Company name

Ratings

Analysts

Leap Therapeutics Inc

LPTX

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Ionis Pharmaceuticals Inc

IONS

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Sell

Sell(8)

Neutral(1)

Buy(1)

Indicators

Sell(3)

Neutral(1)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.005

Sell

RSI(14)

39.799

Neutral

STOCH(KDJ)(9,3,3)

17.188

Oversold

ATR(14)

0.027

High Vlolatility

CCI(14)

-221.106

Oversold

Williams %R

77.731

Sell

TRIX(12,20)

0.042

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

0.322

Buy

MA10

0.338

Sell

MA20

0.336

Sell

MA50

0.349

Sell

MA100

0.360

Sell

MA200

1.323

Sell

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing targeted and immuno-oncology therapeutics. Its advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-related protein 1 (DKK1) protein. DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. Its second clinical-stage program is FL-301, a humanized monoclonal antibody targeting Claudin18.2, being developed in patients with gastric and pancreatic cancer. It also has two preclinical antibody programs, FL-302 and FL-501. FL-302 is a Claudin18.2/CD137 (also known as 4-1BB) bispecific antibody that is in preclinical development. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses.

Ticker SymbolLPTX

CompanyLeap Therapeutics Inc

CEOMr. Douglas E. (Doug) Onsi

Websitehttps://www.leaptx.com/